Therapeutic biologic for treatment of hepatocellular carcinoma
AssigneeCircular Commitment Company
InventorsKuo-Jang Kao, Yun-Hsin Wang
Life of this patent
Estimating the term…
Abstract
Conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein, and methods of using such conjugates, including methods of treating HCC by administering the conjugates or compositions thereof, such as pharmaceutical compositions.
Claims7
A method of treating hepatocellular carcinoma (HCC) in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of a conjugate comprising a tissue factor (TF) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 1 conjugated via a linker peptide to an antibody that binds an extracellular domain epitope of human plasmalemma vesicle associated protein (PLVAP) having the sequence set forth in SEQ ID NO:
- 25 or SEQ ID NO:
- 26, wherein the conjugate is infused directly into one or more tumor-feeding arteries, and wherein the antibody comprises:
- a) complementarity determining regions (CDRs) 1-3 of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 3, and CDRs 1-3 of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 4;
- or
- b) CDRs 1-3 of the HCVR comprising the amino acid sequence of SEQ ID NO:
- 5, and CDRs 1-3 of the LCVR comprising the amino acid sequence of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.